Publications by authors named "P Ussetti"
Introduction: Trough blood levels (C) of tacrolimus are used to adjust drug dosage, but they do not consistently correlate with clinical outcomes. Measurement of residual gene expression of nuclear factor of activated T cell (NFAT)-regulated genes (NFAT-RGE) has been proposed as a pharmacodynamic biomarker to assess the degree of immunosuppression in certain solid organ transplantations, but little is known regarding lung transplant recipients (LTR). Our primary objective is to correlate tacrolimus blood levels with NFAT-RGE.
View Article and Find Full Text PDFMesenchymal stromal cells (MSC) have immunomodulatory and tissue-regenerative properties and have shown promising results in acute respiratory distress syndrome (ARDS) of multiple causes, including COVID-19. We conducted a randomised (1:1), placebo-controlled, double-blind clinical trial to assess the efficacy and safety of one bone marrow-derived MSC infusion in twenty patients with moderate to severe ARDS caused by COVID-19. The primary endpoint (increase in PaO2/FiO2 ratio from baseline to day 7, MSC 83.
View Article and Find Full Text PDFBackground: The clinical benefits of the common off-label use of cytomegalovirus (CMV)-specific immunoglobulin (CMV-Ig) combined with antivirals in organ transplantation have not been previously assessed. The objective was to compare the risk of CMV infection and other post-transplantation outcomes between two CMV-Ig prophylaxis regimens in lung transplant recipients; Methods: Retrospective study of 124 donor CMV positive/recipient negative (D+/R-) patients receiving preventive ganciclovir/valganciclovir for 12 months, of whom 62 received adjunctive CMV-Ig as per label indication (short regimen [SR-Ig]; i.e.
View Article and Find Full Text PDFArticle Synopsis
- The CMV Symposium in September 2021 was a big meeting where experts talked about cytomegalovirus (CMV) infections in people who had organ transplants.
- They covered important topics like how CMV spreads, how to diagnose it, and how it affects patients after their transplants.
- Recent improvements in preventing and treating CMV are helping patients feel better, and in the future, treatments could be tailored to each patient’s specific immune system needs.
Article Synopsis
- Chronic lung allograft dysfunction (CLAD) leads to a decreasing forced expiratory volume in 1 second (FEV1) and is linked to higher mortality rates in lung transplant patients.
- The study analyzed a decade of data from 130 lung transplant recipients to explore how changes in FEV1 relate to the risk of dying after transplantation.
- Results showed that each 1% drop in FEV1 correlates with a 3.4% rise in mortality risk, suggesting that FEV1 could be a key indicator for predicting patient outcomes and guiding early treatment strategies.